

Beyond the Ejection Fraction : A practical Guide to Assessing Diastolic Function & Filling Pressure

Hasanah Mumpuni, MD

Dr. Sardjito Hospital / FK-KMK UGM - Yogyakarta

☎ 0811-1900-8855

✉ scientific_ihefcard@inahfcardmet.org

📷 @ina.hf

www.ihefcard.com

11-13 JUNE 2026

Sheraton Grand Jakarta, Gandaria City

Why diastolic still matters

**Dyspnea is common.
Filling pressure is the
bridge.**

The practical question is rarely
“does relaxation exist?”
It is: “are pressures normal now,
or will they rise with stress?”

Relaxation

active, time-dependent

Elastic recoil

early suction

Compliance

volume at low pressure

HFpEF diagnosis requires symptoms, phenotype, natriuretic peptides, and echo context — not a single Doppler number.

Elevated LAP explains exertional dyspnea, pulmonary venous congestion, and prognosis.

Reports should answer normal vs abnormal diastolic function, grade, and estimated filling pressure when possible.

Sources: ASE 2016, ASE 2025

“Filling pressure” is not one number




Fig. 9 Relative changes in LA and LV diastolic pressures in different stages of impaired diastolic function. LAP remains normal when relaxation is impaired but becomes elevated when LV compliance is decreased. [42] Adapted from Panesar, Dilveer and Burch

LVEDP

End-diastolic LV pressure


Can be isolated early in disease
Reflects chamber stiffness at end-diastole
May rise **before** mean LAP

Sources: ASE 2025

Mean LAP / PCWP


Mean left atrial / wedge pressure

Closest to pulmonary congestion
Often what echo algorithms estimate
Invasive abnormal at rest: PCWP >15 mmHg



GUIDELINES AND STANDARDS

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography



Sherif F. Nagueh, MD, FASE (Chair), Danita Y. Sanborn, MD, FASE (Co-Chair), Jae K. Oh, MD, FASE, Bonita Anderson, MAppSc, DMU, ACS, FASE, FASA, Kristen Billick, BS, ACS, RCS, RDCS, FASE, Genevieve Derumeaux, MD, PhD, Allan Klein, MD, FASE, Konstantinos Koulogiannis, MD, FASE, Carol Mitchell, PhD, ACS, RDMS, RDCS, RVT, RT(R), FASE, Amil Shah, MD, Kavita Sharma, MD, Otto A. Smiseth, MD, PhD, Honorary FASE, and Teresa S. M. Tsang, MD, FASE, *Houston and Dallas, Texas; Boston, Massachusetts; Rochester, Minnesota; Brisbane, Australia; San Diego, California; Creteil, France; Cleveland, Ohio; Morristown, New Jersey; Madison, Wisconsin; Baltimore, Maryland; Oslo, Norway; and Vancouver, British Columbia, Canada*

Echocardiographic correlates with mean PCWP and with LVEDP

PCWP, mean LAP, LV pre-A, and
mean LV diastolic pressure
correlates


LVEDP correlates

1. Mitral peak E velocity	1. Mitral peak A velocity at tips level
2. Mitral E/A ratio	2. A-wave duration at the annulus
3. Mitral E velocity deceleration time	3. Mitral A velocity (tips level) deceleration time
4. Mitral E/e' ratio	4. Pulmonary vein peak Ar velocity
5. Pulmonary vein systolic-to-diastolic velocity ratio	5. Pulmonary vein Ar duration – mitral A duration
6. Peak TR velocity and PASP	6. LA minimum volume
7. End-diastolic velocity of PR and PADP	7. Tissue Doppler-derived mitral annular a' velocity
8. LARS	8. LA pump (or contractile) strain

- The term LV filling pressure refers to mean LAP or its correlates (mean PCWP, LV pre-A pressure).
- LVEDP and LAP are not the same.
- Elevated LAP is always associated with elevated LVEDP in patients with diastolic dysfunction, elevated LVEDP may be present when LAP is normal.

Nagueh et al Journal of the American Society of Echocardiography, July 2025

2025 ASE: diagnosing LV diastolic dysfunction



* : can also consider age specific cutoff values to identify abnormally reduced e' velocity or abnormally reduced E/A ratio
 : after excluding LA enlargement in athletes, or due to anemia, atrial fibrillation or flutter, and mitral valve disease
 ¶ : another finding consistent with diastolic dysfunction: LV mass index >95 g/m² in women or 115 g/m² in men, after exclusion of increased LV mass in athletes

Nagueh et al Journal of the American Society of Echocardiography, July 2025


Simplified from ASE 2025 Figure 3; exceptions and supplemental parameters should be checked in the guideline.

2025 ASE: diagnosing LV diastolic dysfunction

LV Diastolic Function Grading & LAP Estimation

1. Reduced e' velocity: septal ≤ 6 or lateral ≤ 7 or average ≤ 6.5 cm/s *
2. Increased E/e' : septal ≥ 15 or lateral ≥ 13 or average ≥ 14
3. Increased TR velocity ≥ 2.8 m/s or PASP ≥ 35 mm Hg

Except in
MAC, MR, MS[†]
Atrial Fibrillation
LVAD
Non-cardiac PH
HTX
Pericardial
constriction



Simplified from ASE 2025 Figure 3; exceptions and supplemental parameters should be checked in the guideline.

Nagueh et al Journal of the American Society of Echocardiography, July 2025

2025 ASE: estimating mean LAP and grading

Three primary signals

Reduced e' velocity

Average E/e' ≥ 14

TR Vmax ≥ 2.8 m/s or PASP ≥ 35

How many are abnormal?

0/3

Normal LAP

Normal DF

Reduced e' only

Normal LAP

Grade 1

2/3 or 3/3

Elevated LAP

Grade 2 if E/A < 2
Grade 3 if E/A ≥ 2

Discordant

Use supplemental
parameters or stress echo


LAVi, LARS, PV flow, IVRT,
Valsalva

Do not apply the general algorithm uncritically in severe primary MR, mitral stenosis, moderate/severe MAC, AF, LVAD, non-cardiac PH, transplant, or constriction.

Source from ASE 2025

e'

A practical marker of LV relaxation that is less load-dependent than transmitral flow, but not load-independent.



Average e'	$\leq 6.5 \text{ cm/s}$
--------------	-------------------------

Caveats: annular calcification, prosthetic rings, regional wall motion abnormality, constriction, pacing/LBBB, and mitral valve disease.

Sources: ASE 2025

E/e'

Approximate relation: transmitral
pressure gradient / annular
relaxation velocity

Average E/e' ≥ 14

supports elevated LAP in the general
algorithm



When E/e' can mislead

- Heavy MAC
- Prosthetic mitral rings
- Mitral stenosis
- Primary MR and severe secondary MR
- Constrictive physiology
- HCM
- pacing/LBBB
- Young healthy patients and marked preload shifts

Left atrial volume index

>34 mL/m²

Chronic exposure to elevated filling pressures but enlarged LA can reflect AF, MR, anemia, athletic remodeling, high-output states.




The left atrium: pressure memory and reservoir function

LARS

LA reservoir strain

≤18%

Dynamic functional marker
increasingly incorporated in
contemporary algorithms; high
specificity for elevated LAP but
vendor/training quality matters.



Sources: ASE 2025


TR velocity and pulmonary venous flow

TR velocity / PASP

Elevated LAP can transmit to pulmonary circulation, but TR velocity also **reflects pulmonary vascular and RV disease**.

**TR Vmax ≥ 2.8 m/s
or PASP ≥ 35 mmHg**

Use with RAP estimate and clinical context.



TR velocity and pulmonary venous flow


Pulmonary venous flow

S/D ratio reduced systolic dominance can support elevated LAP.

Ar-A duration >30 ms suggests elevated LVEDP.

Best use as supplemental evidence when primary parameters conflict or are missing.

Practical caveat PV flow is technically demanding and rhythm/mitral disease sensitive.



2025 ASE: LAP estimation in Atrial Fibrillation

1. Mitral E velocity ≥ 100 cm/s
2. Septal E/e' ratio > 11
3. TR velocity > 2.8 m/s or PASP > 35 mm Hg
4. DT ≤ 160 ms

None or 1 of above

2 of above

3 or more of above

LARS $< 18\%$
Pulm vein S/D ratio < 1
BMI > 30 kg/m²

None

1 only or not available or
not reliable

2/3 or 3/3

Normal LAP

Indeterminate

Elevated LAP

Source from ASE 2025 Figure 8

2025 ASE: LAP estimation in Pulmonary Hypertension





Figure 6 Algorithm for estimation of mean LAP in patients with PH.

Source: from ASE 2025 Figure 6

Algorithm for HFpEF diagnosis


Multimodality imaging and cardiac catheterization should be used as needed to establish the presence of alternative diagnoses to HFpEF



Source: from ASE 2025 Figure 9

HFpEF: The Algorithm

The HFA-PEFF Algorithm for the Diagnosis of HFpEF



	Functional	Morphological	Biomarker (SR)	Biomarker (AF)
Major	septal e' < 7 cm/s or lateral e' < 10 cm/s or Average E/e' ≥ 15 or TR velocity > 2.8 m/s (PASP > 35 mmHg)	LAVI > 34 ml/m ² or LVMi ≥ 149/122 g/m ² (m/w) and RWT > 0,42 #	NT-proBNP > 220 pg/ml or BNP > 80 pg/ml	NT-proBNP > 660 pg/ml or BNP > 240 pg/ml
Minor	Average E/e' 9 -14 or GLS < 16 %	LAVI 29-34 ml/m ² or LVMi > 115/95 g/m ² (m/w) or RWT > 0,42 or LV wall thickness ≥ 12 mm	NT-proBNP 125-220 pg/ml or BNP 35-80 pg/ml	NT-proBNP 365-660 pg/ml or BNP 105-240 pg/ml
Major Criteria: 2 points		≥ 5 points: HFpEF		
Minor Criteria: 1 point		2-4 points: Diastolic Stress Test or Invasive Haemodynamic Measurements		

HFpEF: The Algorithm

	Functional	Morphological	Biomarker (SR)	Biomarker (AF)
Major	septal $e' < 7$ cm/s or lateral $e' < 10$ cm/s or Average $E/e' \geq 15$ or TR velocity > 2.8 m/s (PASP > 35 mmHg)	LAVI > 34 ml/m ² or LVMI $\geq 149/122$ g/m ² (m/w) and RWT $> 0,42$ #	NT-proBNP > 220 pg/ml or BNP > 80 pg/ml	NT-proBNP > 660 pg/ml or BNP > 240 pg/ml
Minor	Average $E/e' 9-14$ or GLS $< 16\%$	LAVI $29-34$ ml/m ² or LVMI $> 115/95$ g/m ² (m/w) or RWT $> 0,42$ or LV wall thickness ≥ 12 mm	NT-proBNP $125-220$ pg/ml or BNP $35-80$ pg/ml	NT-proBNP $365-660$ pg/ml or BNP $105-240$ pg/ml
Major Criteria: 2 points		≥ 5 points: HFpEF		
Minor Criteria: 1 point		2-4 points: Diastolic Stress Test or Invasive Haemodynamic Measurements		

Diastolic stress echo


iHFF

Indication

Unexplained exertional dyspnea with nondiagnostic or normal resting filling pressure assessment, especially when HFpEF remains clinically plausible.

The physiology:
stiff LV → disproportionate pressure rise during exercise.

Advanced HFpEF workup: Echo stress test



HFA-PEFF consensus 2019

Special populations



Table 7 Indicators of elevated LV filling pressures in special populations

Disease	Echocardiographic measurements indicative of elevated LV filling pressure
1. Atrial fibrillation ⁴⁰⁻⁴²	1. DT < 160 ms in patients with depressed LVEF 2. Peak acceleration rate of mitral E velocity ($\geq 1,900 \text{ cm/s}^2$) 3. IVRT ($\leq 65 \text{ ms}$) 4. DT of pulmonary venous diastolic velocity ($\leq 220 \text{ ms}$) 5. E/Vp ratio (≥ 1.4) 6. Septal E/e' ratio (≥ 11) 7. Peak TR velocity > 2.8 m/s
2. Sinus tachycardia ^{43,44}	1. Predominant early LV filling pattern with depressed LVEF 2. IVRT $\leq 70 \text{ ms}$ is specific (79%) 3. Pulmonary vein systolic filling fraction $\leq 40\%$ is specific (88%) 4. Average E/e' ratio > 14 (high specificity but low sensitivity) 5. When E and A velocities are partially or completely fused, the presence of a compensatory period after premature beats often leads to separation of E and A velocities which can be used for assessment of diastolic function
3. HCM ⁴⁵	1. Average E/e' (>14) 2. Ar-A ($\geq 30 \text{ ms}$) 3. Peak TR velocity (>2.8 m/s) 4. LA maximum volume index (>34 mL/m²)

Source from ASE 2025 Table 7

Special populations

Table 7 Indicators of elevated LV filling pressures in special populations

Disease	Echocardiographic measurements indicative of elevated LV filling pressure
4. Restrictive cardiomyopathy ⁴⁶⁻⁴⁹	1. Average E/e' (>14) 2. $DT < 140$ ms* 3. E/A ratio $> 2.5^*$ 4. $IVRT < 50$ ms*
5. PH ^{50,51}	1. $E/A \geq 2$ favors postcapillary PH 2. $E/A \leq 0.8$ favors precapillary PH 3. When E/A ratio is >0.8 but <2, lateral E/e' ratio > 13, LA maximum volume index > 34 mL/m², and LARS $< 18\%$ favor the diagnosis of postcapillary PH.
6. Mitral stenosis ⁵²	1. $IVRT < 60$ ms* 2. Mitral A peak velocity > 1.5 m/s 3. $IVRT/T_{E-e'}$ ratio < 4.2
7. MR ⁵²⁻⁵⁴	1. $IVRT < 60$ ms* 2. Ar-A (≥ 30 ms) 3. $IVRT/T_{E-e'}$ ratio < 5.6 4. Average E/e' ratio > 14 in patients with depressed EF

Source from ASE 2025 Table 7

Special populations



Table 7 Indicators of elevated LV filling pressures in special populations

Disease	Echocardiographic measurements indicative of elevated LV filling pressure
8. Moderate/severe MAC ⁵⁵	1. LV filling pressure normal when mitral E/A ratio is <0.8 2. LV filling pressure elevated when mitral E/A ratio is >1.8 3. E/A ratio >0.8 but <1.8, IVRT should be measured. LV filling pressure normal when IVRT is ≥ 80 ms, whereas it is elevated if IVRT <80 ms.
9. LV assist device ^{56,57}	1. E/A ratio > 2 2. RAP > 10 mm Hg 3. PASP > 40 mm Hg 4. Average E/e' ratio > 14 or septal E/e' ratio ≥ 15 5. LA maximum volume index > 33 mL/m² 6. Interatrial septum position[†]
10. Cardiac transplant recipients ⁵⁸	1. Average E/e' ratio < 7 denotes normal LV filling pressures 2. Average E/e' ratio > 14 denotes elevated LV filling pressures 3. For E/e' ratio > 7 and <14, SR_{IVR}, from all three apical views, is measured, and the ratio of mitral E velocity to SR_{IVR} is derived. A ratio ≤ 200 cm is consistent with normal LV filling pressure, but >200 cm denotes elevated LV filling pressure. 4. In patients in whom SR_{IVR} cannot be measured, peak TR velocity is relied on. Peak TR velocity ≤ 2.8 m/s is consistent with normal LV filling pressures, but >2.8 m/s denotes elevated LV filling pressures.

*Specific but not sensitive indicators of elevated LV filling pressure.

[†]LAP = RAP if the interatrial septum position is neutral. If septum bulges to right, then LAP is 5 mm Hg higher than RAP. If septum bulges to left, then LAP is 5 mm Hg lower than RAP.

Key Messages

- **Diastolic** is pressure-gradient physiology
- **LV filling pressure** refers to mean LAP or its correlates (mean PCWP, LV pre-A pressure).
- Elevated LAP is always associated with elevated LVEDP in patients with diastolic dysfunction, elevated LVEDP may be present when LAP is normal
- LVEDP and LAP are not the same.
- The 2025 ASE approach is more structured and incorporates LA strain, reflecting **filling pressure** → used to diagnosing **HFpEF**

References

Nagueh SF, Sanborn DY, Oh JK, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for HFpEF Diagnosis: An Update From ASE. *J Am Soc Echocardiogr*. 2025;38:537–569. doi:10.1016/j.echo.2025.03.011

Robinson S, Ring L, Oxborough D, et al. The assessment of left ventricular diastolic function: guidance and recommendations from the British Society of Echocardiography. *Echo Res Pract*. 2024;11:16. doi:10.1186/s44156-024-00051-2

Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of LV diastolic function by echocardiography: ASE/EACVI update. *J Am Soc Echocardiogr*. 2016;29:277–314. doi:10.1016/j.echo.2016.01.011

Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose HFpEF: the HFA–PEFF diagnostic algorithm. *Eur Heart J*. 2019;40:3297–3317. doi:10.1093/eurheartj/ehz641

Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of HFpEF. *Circulation*. 2018;138:861–870. doi:10.1161/CIRCULATIONAHA.118.034646

Pai, R. G., & Varadarajan, P. (2024). Diastolic Heart Failure Mechanisms and Assessment Revisited. In *Journal of Clinical Medicine* (Vol. 13, Number 11). Multidisciplinary Digital Publishing Institute (MDPI). <https://doi.org/10.3390/jcm13113043>

Alhamdulillah THANK YOU

Indonesian Symposium
on Heart Failure and
Cardiometabolic Disease

☎ 0811-1900-8855

✉ scientific_ihefcard@inahfcardmet.org

📷 @ina.hf

www.ihefcard.com

11-13 JUNE 2026

Sheraton Grand Jakarta, Gandaria City